Verge Genomics and Eli Lilly expand their ALS collaboration, with Verge’s AI-driven CONVERGE® platform identifying therapeutic targets. This milestone triggers milestone payments and potential royalties for Verge as Lilly moves forward with ALS drug development.

Stream unavailable
Eli Lilly Advances ALS Drug Development with Verge Genomics’ AI-Powered Target Identification – Draper Decentralized – 12.3.24
Published December 3, 2024